Tiziana Life Sciences announces updated intranasal foralumab data

Tiziana Life Sciences (TLSA) announced updated clinical data from its ongoing expanded access program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis. The data, updated from March 2025 to as of March 2026, demonstrate that intranasal foralumab continues to be extremely well tolerated over extended treatment durations. Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale. Foralumab was well tolerated with no new safety signals identified. The company observed a favorable trend toward disease stabilization. Overall, 64% of patients achieved a clinically meaningful improvement of greater than or equal to four points in their MFIS score.